Pricing Log in Create free account
Saturday 17 October 2026 Export MRKR’s income statement to Excel — free account

MARKER THERAPEUTICS, INC.

MRKR Healthcare Biotechnology

In the quarter to June 2026, revenue grew 2.75%, EPS grew 69.0% and free cash flow fell 97.8%, each against the same quarter a year earlier.

1.04 0.12 +13.04%
Market cap
$15.3M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−28.68
Beneish M
−2.92
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 30.11%

Capital & Financial Ratios $m

Market Cap 15.34
Revenue 4.76
Net Income (8.71)
Free Cash Flow (9.76)
Net Debt (11.12)
Current Ratio 6.03 (at or above 1.5: strong)
Debt/Equity 0.07 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.47) (negative: loss-making)
P/S ratio 4.22
P/B ratio 1.65
Past 5Y EPS Growth —
This Y EPS Growth 24.89% (at or above 15%: strong)
Next Y EPS Growth (47.75%) (below 0%: weak)
Next Y revenue growth 19.60% (at or above 10%: strong)
Next 5Y EPS Growth 10.26%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.9×, against a ten-year median of 3.1×; over the ten years it ranged from −6.5× in 2022 to 164× in 2021.
P/S against its own 10 years 18.13%
10-year low 10-year high
P/B against its own 10 years 27.37%
10-year low 10-year high
EV/Sales against its own 10 years 25.16%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 15 19 17 12
Receivables 1 2 1 2
Inventory — — — —
Other — — — —
17 22 19 15
2023 2024 2025 Q'26
Payables 2 2 1 1
ST’ Debt — 2 — 1
Other — — — —
3 3 2 2

Compound Annual Growth %

10y 5y 3y
Sales — 50.02% 0.31%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (9.29%) (5.02%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 0 1 1 2 4
’24 1 1 2 2 7
’23 1 1 0 1 3
’22 1 1 1 1 4
’21 — — — 1 1
’20 — 0 — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (4) — — —
’25 (5) (2) (3) (2) (12)
’24 (4) (4) 1 (5) (11)
’23 (6) (7) (1) (2) (16)
’22 (12) (1) (8) (6) (27)
’21 (8) (7) (8) (5) (27)
’20 (4) (4) (6) (6) (20)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (4) — — —
’25 (5) (2) (3) (2) (12)
’24 (4) (4) 1 (5) (11)
’23 (6) (7) (1) (2) (16)
’22 (15) (3) (12) (11) (32)
’21 (10) (7) (9) (5) (30)
’20 (4) (8) (7) (10) (29)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.09) — — —
’25 (0.40) (0.29) (0.12) (0.04) (0.79)
’24 (0.27) (0.25) (0.26) (0.42) (1.19)
’23 (0.57) 0.29 (0.34) (0.31) (0.94)
’22 (1.20) (1.10) (0.80) (0.46) (3.58)
’21 (1.60) (1.30) (1.50) (1.20) (5.50)
’20 (1.40) (1.40) (1.60) (1.80) (6.10)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 33.20 26.00 25.80 26.10 13.20 9.00 2.20 0.67 2.44 0.81

Analyst estimates 2026–2028

Powerpack
High 98.40 53.50 135.50 91.70 33.90 37.70 10.30 9.68 5.99 4.07
People
People Employees 8 7 11 28 44 56 67 8 5 5
Revenue/emp, $m 0.00 0.03 0.02 0.01 0.01 0.02 0.05 0.41 1.32 0.71
Income, $m
Income, $m Revenue — 0 0 0 0 1 4 3 7 4
Gross margin, % — 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (2) (11) (148) (21) (29) (42) (20) (14) (11) (12)
EBT margin, % 0.00 (5,997.92) (71,824.22) (10,050.66) (6,149.55) (3,372.71) (562.85) (424.09) (162.06) (343.38)
Net income (2) (11) (148) (21) (29) (42) (30) (8) (11) (12)
Depreciation — — — 0 1 3 — — — —
Per share, $
Per share, $ Revenue 0.00 0.19 0.11 0.05 0.10 0.16 0.42 0.38 0.73 0.23
Earnings (3.60) (11.60) (77.50) (4.70) (6.10) (5.50) (3.58) (0.94) (1.19) (0.79)
Cash flow (9.45) (8.93) (7.58) (4.01) (4.26) (3.57) (3.23) (1.87) (1.21) (0.78)
Capex 0.00 0.00 (0.08) (0.08) (1.97) (0.41) (0.59) 0.00 0.00 0.00
Free cash flow (9.45) (8.93) (7.66) (4.09) (6.23) (3.97) (3.82) (1.87) (1.21) (0.78)
Book value 8.98 3.87 31.08 9.67 5.81 5.75 2.35 1.60 2.07 1.10
Shares, m 1 1 2 5 5 8 8 9 9 15
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 0.00 0.00 0.00 63.80 34.16 6.66 14.53 4.24 4.80
P/B — 10.52 1.79 2.98 2.49 1.65 1.19 3.42 1.50 1.36
EV/Sales — 0.00 0.00 0.00 44.19 14.01 3.47 10.16 1.58 1.57
EV/FCF — (3.95) (3.05) (4.69) (1.61) (0.98) (0.29) (1.18) (0.45) (0.31)
Cash, $m
Cash, $m Operating cash flow (7) (8) (14) (18) (20) (27) (27) (16) (11) (12)
Capex — — 0 0 (9) (3) (5) — — —
Free cash flow (7) (8) (15) (19) (29) (30) (32) (16) (11) (12)
Balance, $m
Balance, $m Working capital 6 4 59 43 18 33 9 14 19 17
Total debt 0 — — 0 0 1 1 — 2 —
Net debt (8) (5) (62) (44) (21) (43) (11) (15) (17) (17)
Shareholders’ equity 6 4 59 44 27 44 20 14 19 17
Returns, %
Returns, % ROA (33.71) (167.64) (439.54) (39.50) (62.42) (73.63) (58.37) (31.96) (54.82) (59.20)
ROIC 0.00 0.00 0.00 (3,644.97) (282.93) (2,225.27) (147.32) 0.00 (645.52) 0.00
ROE 32.36 (223.15) (469.72) (41.44) (80.37) (117.42) (94.14) (48.95) (65.81) (68.81)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

MARKER THERAPEUTICS, INC. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PBM Psyence Biomedical Ltd. $16.5M 0.2× — — n/m −707.20% (below 0%: shrinking) — 0.00% Compare
TCRX TScan Therapeutics, Inc. $16.2M — (loss-making) — (loss-making) −65.83% (below 0%: shrinking) n/m +18.95% (above 0%: growing) 100.00% (2,901.33%) Compare
AKTX Akari Therapeutics PLC $15.5M — (loss-making) — — n/m +4.51% (above 0%: growing) 0.00% 0.00% Compare
VAXX Vaxxinity, Inc. $15.5M — (loss-making) — (loss-making) −100.23% (below 0%: shrinking) n/m +17.00% (above 0%: growing) 0.00% 0.00% Compare
MRKR MARKER THERAPEUTICS, INC. $15.3M — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m −97.84% (below 0%: shrinking) 100.00% 0.00%
NCEL NewcelX Ltd. $15.3M — (loss-making) — — n/m −87.71% (below 0%: shrinking) 0.00% — Compare
GTBP GT Biopharma, Inc. $15.2M — (loss-making) — −100.00% (below 0%: shrinking) n/m −41.34% (below 0%: shrinking) 0.00% 0.00% Compare
DARE Dare Bioscience, Inc. $14.6M — (loss-making) — (loss-making) +984.43% (above 0%: growing) n/m −30.23% (below 0%: shrinking) (70.56%) (1,582.93%) Compare
ADAPY Adaptimmune Therapeutics PLC $14.6M — (loss-making) — (loss-making) −89.33% (below 0%: shrinking) n/m −174.72% (below 0%: shrinking) 81.71% (221.45%) Compare
Median of peers $15.4M — — −89.33% — −35.78% 0.00% 0.00%

All 614 Biotechnology stocks →

MARKER THERAPEUTICS, INC. (MRKR) key facts

  • MARKER THERAPEUTICS, INC. (MRKR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, MRKR traded at $1.04, a market capitalization of $15.3 million.
  • Return on equity was −68.8% and debt-to-equity 0.07.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −28.68 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

MARKER THERAPEUTICS, INC. (MRKR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MRKR · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com